Tag: HCC

TACE

ET 2019: New data support TACE using microspheres in both HCC...

Transarterial chemoembolization using microspheres appears to show “much better outcomes” than those seen with conventional TACE, both in the setting of hepatocellular carcinoma (HCC)...

New indication approved for Guerbet’s Lipiodol Ultra Fluid

A new indication for Lipiodol Ultra Fluid (Guerbet) has been approved in Switzerland and in India for chemoembolization (cTACE) of tumours in adults with...
HCC

Call for IRs to standardise reporting of procedures to aid HCC...

The lessons learned from a recent research article were outlined in a presentation by interventional radiologist Maxime Ronot (Beaujon University Hospital, Paris, France) at...

Y-90 radioembolization in hepatocellular carcinoma: “Liver function is key”

Jens Ricke (Department of Radiology, University Hospital LMU Munich, Germany) presented the latest evidence about Y-90 radioembolization in hepatocellular carcinoma (HCC) at the 2019...

Patients prefer transradial access to transfemoral, study finds

Patients have a strong preference for transradial access, a recent study published in the Journal of Vascular and Interventional Radiology finds. Lead author Lisa...
stereotactic

Stereotactic radiofrequency ablation is effective even in tumours over 3cm, study...

Multi-probe stereotactic radiofrequency ablation (SRFA) with intraprocedural image fusion represents an efficient minimally invasive therapy for hepatocellular carcinoma (HCC), even with tumour sizes larger...
microwave

Retrospective review suggests microwave ablation of HCC in the elderly is...

Treating hepatocellular carcinoma (HCC) with microwave ablation is safe in the elderly population, the first study investigating the efficacy and safety profile of this...
radiofrequency

CT-guided radiofrequency thermal ablation a safe alternative to surgery for HCC...

Percutaneous CT-guided radiofrequency thermal ablation is a safe and effective alternative treatment option in patients with pulmonary metastases from hepatocellular carcinoma (HCC) that cannot...

US FDA grants Breakthrough Therapy Designation for combination immunotherapy in HCC...

Roche has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)...

Establishing the evidence base for SIRT in Interventional Oncology

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

New data demonstrate clinical experience with LifePearl microspheres in over 300...

Transarterial chemoembolization (TACE) using LifePearl (Terumo) drug-eluting embolic agents in the treatment of hepatocellular carcinoma has just been published.

International survey reveals high variability in TACE technique

Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...
randomised

Radiation segmentectomy offers new treatment option for liver cancer

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

Guerbet announces Lausanne partnership to evaluate immunogenic potential of cTACE

Guerbet has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne's University Hospital (CHUV) and the Lausanne Center for Experimental...

Terumo Europe NV announces approval of LifePearl as a Class III...

This approval also expands the number of chemotherapeutic drugs that can be loaded onto LifePearl to include idarubicin and epirubicin, a press release from...

Northwestern University adopts radioembolization with TheraSphere as first-line treatment for HCC

BTG has announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere, Northwestern University, Illinois, USA, has adopted Y-90...

Theoretical benefit with microwave ablation “does not translate into clinical benefit”...

A prospective randomised controlled study that compared outcomes between hepatocellular carcinoma patients who were treated by microwave ablation with those who were treated by...

Vast majority of patients prefer radial access for embolization therapies in...

“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...
ablation

Dexamethasone treatment prevents TACE side-effects in hepatocellular carcinoma patients

A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in...

German Federal Institute for Drugs and Medical Devices approves new indication...

Guerbet has announced that the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM; The German Federal Institute for Drugs and Medical Devices) has now approved Lipiodol...

SIRT significantly better tolerated than sorafenib, but does not increase overall...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

Surefire closes US$12.8 million funding, to present new data at SIR

Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing...

SARAH study results to be presented as oral abstract at April...

Sirtex has announced that the SARAH (Sorafenib vs. radioembolisation in advanced hepatocellular carcinoma) randomised controlled study results will be presented at the upcoming European...